Tivdak (tisotumab vedotin) has received approval from the Japanese Ministry of Health. This means that the treatment is the first and only antibody-drug conjugate (ADC) to be approved for people living with cervical cancer in Japan.
The approval is based on data from a randomized study showing that the treatment reduces the risk of death by 30 pro...
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration